Approved by the FDA in 1999, Actos is a Type 2 diabetes medication, manufactured by Takeda, which has been hailed for years as one of the most effective Type 2 diabetes treatments and has been a huge financial success for its manufacturer. Actos was, at one point, Takeda’s best selling drug, and has been called one of the best selling drugs of all time. However, according to the website of Williams Kherkher, Actos has, in recent years, been linked to a substantially increased risk of developing bladder cancer, among other dangerous side effects.

A study published in 2012 found that people who took Actos for an extended period of time were 83% more likely to develop bladder cancer. After which, the FDA ordered a 10-year study on the safety of the drug, in relation to bladder problems and cancer.

In 2011, the FDA ruled that Takeda, the drug’s manufacturer and marketer, needed to update Actos’ warnings and precautions to include increased risk of bladder cancer. Actos has also been linked to congestive heart failure and kidney disease. It is now recommended by many to avoid Actos in all instances except as a last resort effort to treat Type 2 diabetes, when all other options have been exhausted.

Victims of negligence on behalf of pharmaceutical companies often suffer severely, according to the website of Williams Kherkher, as is the case with Takeda and its manufacturing of Actos. Lawsuits against Takeda allege that the company failed to disclose critical information about side effects of the drug, and concealed information about its safety, in addition to ineffective testing.

As of April 2015, Takeda had already settled thousands of Actos-related lawsuits, at the price of $2.37 billion. Law firms continue to suits against Takeda for clients who have suffered as a result of taking the drug.


read more